Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Huiying Qiu

Showing results (181-190 of 194) with videos related to

Pageof 20
Sort By:
Frontiers in Immunology|April 4, 2022
Identification of the Predictive Models for the Treatment Response of Refractory/Relapsed B-Cell ALL Patients Receiving CAR-T TherapyJingxian Gu, Sining Liu, Wei Cui, et al.
Scientific Reports|January 11, 2022
The differential effects of tumor burdens on predicting the net benefits of ssCART-19 cell treatment on r/r B-ALL patientsMinghao Li, Sheng-Li Xue, Xiaowen Tang, et al.
Frontiers in Immunology|March 19, 2026
Quantitative evaluation of T-cell repertoire restoration following hematopoietic stem cell transplantation in patients with and without graft versus host diseaseXin Zhang, Pengyi Song, Longhai Tang, et al.
Blood|March 18, 2026
Randomized trial of GvHD Prophylaxis in Haploidentical PBSC Transplantation: ATG, PTCy, and Low-Dose Combination TherapyJun Yang, Yannan Jia, Xiaoxia Hu, et al.
Blood Science (Baltimore, Md.)|June 24, 2024
Ivosidenib in Chinese patients with relapsed or refractory isocitrate dehydrogenase 1 mutated acute myeloid leukemia: a registry studyMingyuan Sun, Qingsong Yin, Yang Liang, et al.
Leukemia & Lymphoma|March 13, 2024
Comparison of valganciclovir <i>versus</i> foscarnet for the treatment of cytomegalovirus viremia in adult acute leukemia patients after allogeneic hematopoietic cell transplantationJinjin Zhu, Mimi Xu, Yuhua Ru, et al.
Discover Oncology|February 21, 2025
Reduced-dose chemotherapy followed by blinatumomab for newly diagnosed philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia: a propensity-matched comparison with hyper-CVADJing Lu, Yu Zhu, Huiying Qiu, et al.
Blood Cancer Journal|April 24, 2023
Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy?Sining Liu, Xinyue Zhang, Haiping Dai, et al.
Journal of Hematology & Oncology|September 1, 2024
Reduced-dose chemotherapy and blinatumomab as induction treatment for newly diagnosed Ph-negative B-cell precursor acute lymphoblastic leukemia: a phase 2 trialJing Lu, Huiying Qiu, Ying Wang, et al.
Haematologica|November 27, 2025
Integrative clinical and molecular characterization of an acute promyelocytic leukemia-like subgroup with high early death risk in newly diagnosed acute myeloid leukemia: a multicenter studyMingkai Shu, Wenjing Ding, Linlin Wang, et al.
Pageof 20

Showing results (181-190 of 194) with videos related to

Sort By:
Pageof 20
Frontiers in Immunology|April 4, 2022
Identification of the Predictive Models for the Treatment Response of Refractory/Relapsed B-Cell ALL Patients Receiving CAR-T TherapyJingxian Gu, Sining Liu, Wei Cui, et al.
Scientific Reports|January 11, 2022
The differential effects of tumor burdens on predicting the net benefits of ssCART-19 cell treatment on r/r B-ALL patientsMinghao Li, Sheng-Li Xue, Xiaowen Tang, et al.
Frontiers in Immunology|March 19, 2026
Quantitative evaluation of T-cell repertoire restoration following hematopoietic stem cell transplantation in patients with and without graft versus host diseaseXin Zhang, Pengyi Song, Longhai Tang, et al.
Blood|March 18, 2026
Randomized trial of GvHD Prophylaxis in Haploidentical PBSC Transplantation: ATG, PTCy, and Low-Dose Combination TherapyJun Yang, Yannan Jia, Xiaoxia Hu, et al.
Blood Science (Baltimore, Md.)|June 24, 2024
Ivosidenib in Chinese patients with relapsed or refractory isocitrate dehydrogenase 1 mutated acute myeloid leukemia: a registry studyMingyuan Sun, Qingsong Yin, Yang Liang, et al.
Leukemia & Lymphoma|March 13, 2024
Comparison of valganciclovir <i>versus</i> foscarnet for the treatment of cytomegalovirus viremia in adult acute leukemia patients after allogeneic hematopoietic cell transplantationJinjin Zhu, Mimi Xu, Yuhua Ru, et al.
Discover Oncology|February 21, 2025
Reduced-dose chemotherapy followed by blinatumomab for newly diagnosed philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia: a propensity-matched comparison with hyper-CVADJing Lu, Yu Zhu, Huiying Qiu, et al.
Blood Cancer Journal|April 24, 2023
Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy?Sining Liu, Xinyue Zhang, Haiping Dai, et al.
Journal of Hematology & Oncology|September 1, 2024
Reduced-dose chemotherapy and blinatumomab as induction treatment for newly diagnosed Ph-negative B-cell precursor acute lymphoblastic leukemia: a phase 2 trialJing Lu, Huiying Qiu, Ying Wang, et al.
Haematologica|November 27, 2025
Integrative clinical and molecular characterization of an acute promyelocytic leukemia-like subgroup with high early death risk in newly diagnosed acute myeloid leukemia: a multicenter studyMingkai Shu, Wenjing Ding, Linlin Wang, et al.
Pageof 20